TNFSF13B and neoplasm: NSG mice bearing subcutaneous MCL tumors (Jeko-1) were administered BAFF CAR-T cells either intravenously or intratumorally, and human T cells were infused intravenously on day 15 after tumor inoculation (Fig. 7A).